Role of Environment in Pediatric Rheumatic Diseases

2022 ◽  
Vol 48 (1) ◽  
pp. 287-304
Author(s):  
Colleen K. Correll
Keyword(s):  
Rheumatic Diseases

scholarly journals SAT0636-HPR PATIENT EXPERIENCE WITH THE PRESCRIPTION, INFORMATION AND USE OF METHOTREXATE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1277.3-1278
Author(s):  
T. Oton ◽  
L. Carmona ◽  
J. L. Andréu Sánchez
Keyword(s):  
Side Effects ◽  
Focus Groups ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Physical Symptoms ◽  
Number Of Factors ◽  
Graphic Information ◽  
Main Barrier ◽  
And Training

Background:Methotrexate (MTX) is currently a mainstream drug in the treatment of rheumatic diseases. However, the response to MTX is not universal and may be conditioned by a number of factors, among which adherence could be crucial.Objectives:The aim of this study is to explore adherence to MTX in patients with rheumatic diseases, facilitators and perceived when taking and maintaining the prescription.Methods:A qualitative study of content analysis was performed. Focus groups with patients taking either oral or subcutaneous MTX (being the main or coadjuvant treatment) for any rheumatic disease was performed. The groups were moderated by a rheumatologist that was unknown for the patients. The speech was recorded and transcribed. Subsequently, an inductive coding was performed with the help of Atlas.ti and main themes and sub-themes were extracted, with examples of verbatim anonymized speech.Results:Three focus groups were conducted, with a total of 12 participants, of whom eight were women, seven had rheumatoid arthritis, three had psoriatic arthritis, one had spondyloarthritis, and one had systemic lupus erythematosus. All patients reported an adequate adherence to treatment. The barriers identified were: information in the leaflet, technical language in the consults, difficult access to doctor´s appointment, social environment, side effects and the subcutaneous device. As facilitators, the following aspects were discussed: good predisposition of the physician, reliable graphic information, role of associations and partners support.The unmet needs detected were: problems with travelling, protocols for eventualities, absence of a plan of care, neglection of “non-physical” symptoms, disinformation on side effects and training in complementary aspects.Conclusion:Getting reliable information was the main barrier identified. The environment and side effects may also negatively impact on adherence. Shared decision making is a goal to be achieved in the future in these patients.Disclosure of Interests:Teresa Oton Consultant of: Novartis Farmaceutica, SA, Pfizer, S.L.U., Merck Sharp & Dohme España, S.A., Roche Farma, S.A, Sanofi Aventis, AbbVie Spain, S.L.U., and Laboratorios Gebro Pharma, SA (All trhough institution), Loreto Carmona Grant/research support from: Novartis Farmaceutica, SA, Pfizer, S.L.U., Merck Sharp & Dohme España, S.A., Roche Farma, S.A, Sanofi Aventis, AbbVie Spain, S.L.U., and Laboratorios Gebro Pharma, SA (All trhough institution), José Luis Andréu Sánchez: None declared

The Role of Macrophages in the Rheumatic Diseases

1978 ◽  
Vol 4 (3) ◽  
pp. 499-515
Author(s):  
RALPH SNYDERMAN ◽  
GALE A. MCCARTY
Keyword(s):  
Rheumatic Diseases

scholarly journals The role of Interleukin-12 in immune-mediated rheumatic diseases

Reumatismo ◽  
2011 ◽  
Vol 54 (2) ◽  
Author(s):  
A. Spadaro ◽  
R. Scrivo ◽  
T. Rinaldi ◽  
V. Riccieri ◽  
A. Sili Scavalli ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Interleukin 12 ◽  
Immune Mediated

scholarly journals Role of Microbiome in Rheumatic Diseases

2017 ◽  
Vol 17 (2) ◽  
pp. 58-63 ◽  
Author(s):  
Chi Kit Au ◽  
Tin Lok Lai ◽  
Cheuk Wan Yim
Keyword(s):  
Rheumatoid Arthritis ◽  
Gut Microbiota ◽  
Immune Responses ◽  
Rheumatic Diseases ◽  
Pivotal Role ◽  
Human Gut ◽  
Future Role ◽  
Human Gut Microbiota ◽  
Rheumatic Manifestations

AbstractMajority of rheumatic diseases are complex and multifactorial in etiology. Emerging studies has suggested that the change of human microbiota, especially in the gut, play a pivotal role in its pathogenesis. Dysequilibrium of the gut microbiota triggers the imbalance between pro- and anti- inflammatory immune responses and results in different rheumatic manifestations, such as rheumatoid arthritis (RA) and spondyloarthritis (SpA). In this article, current and future role of the human gut microbiota in rheumatic diseases are discussed.

scholarly journals PATHOGENESIS OF FIBROMYALGIA IN PATIENTS WITH AUTOIMMUNE DISEASES: SCOPING REVIEW FOR HYPOTHESIS GENERATION

2020 ◽  
Vol 1 (1) ◽  
pp. 43-54
Author(s):  
Sakir Ahmed ◽  
Able Lawrence
Keyword(s):  
Rheumatic Diseases ◽  
Scoping Review ◽  
Sleep Disturbances ◽  
Unmet Needs ◽  
Social Defeat ◽  
Hypothesis Generation ◽  
Small Fibre Neuropathy ◽  
Small Fibre ◽  
The Common

Introduction: Fibromyalgia (FM) prevalence is much higher in patients with other rheumatic diseases than in the general population. This leads to increase in the perceived disease activity scores and prevents patients from reaching remission. Elucidating the pathogenesis of such “secondary” FM can help alleviate some unmet needs in these diseases. Methods: MEDLINE and Scopus databases were searched for a scoping review for hypothesis generation regarding the genesis of secondary FM. Results: FM has been postulated to be due to cytokine dysfunction, neurogenic neuroinflammation, stress, including social defeat, sleep disturbances, sympathetic overactivity, and small fibre neuropathy. These factors increase in most autoimmune and autoinflammatory diseases. Further the evidence for the role of these factors in the pathogenesis of FM is seems strong. Metabolic syndrome and mitochondrial dysfunction are also associated with FM, but it is difficult to distinguish between cause and effect. Conclusion: FM is the common phenotype arising from the amalgamation of various aetiologies. Recruitment or amplification of the above 6 factors by various rheumatic diseases may thus lead precipitation of secondary FM in susceptible individuals.

AB0740 The frequency of occult hepatitis b infection in rheumatic diseases and the role of anti-hbc test in routine practice

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A1014.3-A1015
Author(s):  
S. Yilmaz ◽  
K. Sener ◽  
I. Simsek ◽  
M. Cinar ◽  
R. Gumral ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Rheumatic Diseases ◽  
Routine Practice ◽  
Hepatitis B Infection ◽  
Occult Hepatitis ◽  
Occult Hepatitis B
Sign in / Sign up

Export Citation Format

Share Document